secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2026-06-26T10:10:17+00:00
Accession:  0001213900-26-072268
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.01, 5.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences to merge with Noble Africa (Renergen), ASP Isotopes to control combined entity
--------------------------------------------------------------------------------

- ENDRA enters merger with Noble Africa LLC; Merger Sub merges into Noble, with Noble surviving as ENDRA sub.
- Concurrent $50M PIPE investment into Noble from ASPI and institutional investors at $6.57/unit.
- Post-merger, ENDRA renamed Noble Africa Inc.; dual-class stock with Class B having 10 votes/share controlled by ASPI.
- Board set at 7 directors: 5 Noble designees, 1 ENDRA designee, CEO; classified board.
- Closing conditions include ENDRA having $3.8M cash, stockholder approval, SEC registration, and DFC consent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026072268/0001213900-26-072268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000121390026072268/ea0295239-8k425_endra.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-072268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer